NASDAQ:NUVA

NuVasive Stock Forecast, Price & News

$67.85
-0.31 (-0.45 %)
(As of 06/24/2021 04:30 PM ET)
Add
Compare
Today's Range
$67.77
$68.68
50-Day Range
$64.02
$71.72
52-Week Range
$43.11
$72.61
Volume254,397 shs
Average Volume664,704 shs
Market Capitalization$3.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
30 days | 90 days | 365 days | Advanced Chart
Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.


NuVasive logo

About NuVasive

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.16 out of 5 stars

Medical Sector

789th out of 2,105 stocks

Surgical & Medical Instruments Industry

73rd out of 174 stocks

Analyst Opinion: 1.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive
or view top-rated stocks.

What stocks does MarketBeat like better than NuVasive?

Wall Street analysts have given NuVasive a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NuVasive wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for NuVasive
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its quarterly earnings results on Wednesday, May, 5th. The medical device company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.02. The medical device company earned $271.25 million during the quarter, compared to analysts' expectations of $261.12 million. NuVasive had a positive trailing twelve-month return on equity of 6.47% and a negative net margin of 4.70%.
View NuVasive's earnings history
.

How has NuVasive's stock been impacted by Coronavirus (COVID-19)?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NUVA shares have increased by 37.3% and is now trading at $67.85.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NUVA?

13 brokerages have issued twelve-month target prices for NuVasive's stock. Their forecasts range from $48.00 to $80.00. On average, they expect NuVasive's share price to reach $68.43 in the next year. This suggests a possible upside of 0.9% from the stock's current price.
View analysts' price targets for NuVasive
or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 48, Pay $1.44M)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 51, Pay $1.02M)
  • Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $594.94k)
  • Mr. Lucas Vitale, Sr. VP & Chief HR Officer (Age 44, Pay $575.97k)
  • Mr. Massimo Calafiore, Exec. VP of Global Bus. Units
  • Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 41)
  • Mr. Johnson Lai, Chief Information Officer
  • Mr. Sean Freeman, Sr. VP of Strategy & Corp. Devel.
  • Mr. Frank Middeke, Managing Director of DACH
  • Ms. Lisa Pecora, VP & Head of Global Commercial Fin.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a number of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (3.50%), Price T Rowe Associates Inc. MD (2.81%), Thrivent Financial for Lutherans (2.75%), Bank of New York Mellon Corp (2.51%), Dimensional Fund Advisors LP (2.36%) and Victory Capital Management Inc. (2.03%). Company insiders that own NuVasive stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive
.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Bank of New York Mellon Corp, Barclays PLC, Royal Bank of Canada, AQR Capital Management LLC, and Armistice Capital LLC. Company insiders that have sold NuVasive company stock in the last year include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive
or view top insider-selling stocks.

Which institutional investors are buying NuVasive stock?

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Paradice Investment Management LLC, Jennison Associates LLC, Rothschild & Co. Asset Management US Inc., Lisanti Capital Growth LLC, Alberta Investment Management Corp, Fort Washington Investment Advisors Inc. OH, and Loomis Sayles & Co. L P.
View insider buying and selling activity for NuVasive
or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $67.85.

How much money does NuVasive make?

NuVasive has a market capitalization of $3.50 billion and generates $1.05 billion in revenue each year. The medical device company earns $-37,150,000.00 in net income (profit) each year or $1.23 on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,700 workers across the globe.

Does NuVasive have any subsidiaries?

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, and SafePassage.

When was NuVasive founded?

NuVasive was founded in 1997.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

Where are NuVasive's headquarters?

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.